These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37339360)

  • 1. The Effect of Lurasidone on Anxiety Symptoms in Patients With Bipolar Depression: A Post Hoc Analysis.
    Goldberg JF; Siu C; Tocco M; Pikalov A; Loebel A
    J Clin Psychiatry; 2023 Jun; 84(4):. PubMed ID: 37339360
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials.
    Rajagopalan K; Bacci ED; Ng-Mak D; Wyrwich K; Pikalov A; Loebel A
    BMC Psychiatry; 2016 May; 16():157. PubMed ID: 27215976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Lurasidone in Adults Aged 55 Years and Older With Bipolar Depression: Post Hoc Analysis of 2 Double-Blind, Placebo-Controlled Studies.
    Sajatovic M; Forester BP; Tsai J; Kroger H; Pikalov A; Cucchiaro J; Loebel A
    J Clin Psychiatry; 2016 Oct; 77(10):e1324-e1331. PubMed ID: 27529375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis.
    Chapel S; Chiu YY; Hsu J; Cucchiaro J; Loebel A
    Clin Ther; 2016 Jan; 38(1):4-15. PubMed ID: 26730454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study.
    Loebel A; Cucchiaro J; Silva R; Kroger H; Sarma K; Xu J; Calabrese JR
    Am J Psychiatry; 2014 Feb; 171(2):169-77. PubMed ID: 24170221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L; Ketter TA; Cucchiaro J; Loebel A
    J Affect Disord; 2014 Feb; 155():20-7. PubMed ID: 24246116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Adding Lurasidone to Ongoing Therapy With Lithium or Valproate for the Treatment of an Acute Bipolar Depressive Episode: A Post Hoc Analysis of 2 Placebo-Controlled Trials.
    Tocco M; Mao Y
    J Clin Psychopharmacol; 2024 Jul-Aug 01; 44(4):345-352. PubMed ID: 38639433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lurasidone adjunctive with lithium or valproate for bipolar depression: A placebo-controlled trial utilizing prospective and retrospective enrolment cohorts.
    Suppes T; Kroger H; Pikalov A; Loebel A
    J Psychiatr Res; 2016 Jul; 78():86-93. PubMed ID: 27089521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lurasidone and risk of metabolic syndrome: results from short and long-term studies in patients with bipolar depression.
    Tocco M; Newcomer JW; Mao Y; Pikalov A
    CNS Spectr; 2023 Dec; 28(6):680-687. PubMed ID: 36961124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Effectiveness of Long-Term Treatment with Lurasidone in Older Adults with Bipolar Depression: Post-Hoc Analysis of a 6-Month, Open-Label Study.
    Forester BP; Sajatovic M; Tsai J; Pikalov A; Cucchiaro J; Loebel A
    Am J Geriatr Psychiatry; 2018 Feb; 26(2):150-159. PubMed ID: 29146409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sleep Disturbance, Irritability, and Response to Lurasidone Treatment in Children and Adolescents with Bipolar Depression.
    Singh MK; Siu C; Tocco M; Pikalov A; Loebel A
    Curr Neuropharmacol; 2023; 21(6):1393-1404. PubMed ID: 36173066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of lurasidone on functioning and indirect costs in adults with bipolar depression: a post-hoc analysis.
    Niu X; Dembek C; Fan Q; Mao Y; Divino V; Burch S; Tocco M
    J Med Econ; 2022; 25(1):152-159. PubMed ID: 35037813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lurasidone: a review of its use in adult patients with bipolar I depression.
    Sanford M; Dhillon S
    CNS Drugs; 2015 Mar; 29(3):253-63. PubMed ID: 25698146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of lurasidone in bipolar I depression with and without rapid cycling: A pooled post-hoc analysis of two randomized, placebo-controlled trials.
    Kato M; Masuda T; Sano F; Kato T
    J Affect Disord; 2023 Sep; 337():150-158. PubMed ID: 37245552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remission and recovery associated with lurasidone in the treatment of major depressive disorder with subthreshold hypomanic symptoms (mixed features): post-hoc analysis of a randomized, placebo-controlled study with longer-term extension.
    Goldberg JF; Ng-Mak D; Siu C; Chuang CC; Rajagopalan K; Loebel A
    CNS Spectr; 2017 Apr; 22(2):220-227. PubMed ID: 28264739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of lurasidone on meaningful change in health-related quality of life in patients with bipolar depression.
    Calabrese J; Rajagopalan K; Ng-Mak D; Bacci ED; Wyrwich K; Pikalov A; Loebel A
    Int Clin Psychopharmacol; 2016 May; 31(3):147-54. PubMed ID: 26717493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial.
    McIntyre RS; Cucchiaro J; Pikalov A; Kroger H; Loebel A
    J Clin Psychiatry; 2015 Apr; 76(4):398-405. PubMed ID: 25844756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study.
    Tsai J; Thase ME; Mao Y; Ng-Mak D; Pikalov A; Loebel A
    CNS Spectr; 2017 Apr; 22(2):236-245. PubMed ID: 28357969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder.
    Calabrese JR; Pikalov A; Streicher C; Cucchiaro J; Mao Y; Loebel A
    Eur Neuropsychopharmacol; 2017 Sep; 27(9):865-876. PubMed ID: 28689688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY.
    Ketter TA; Sarma K; Silva R; Kroger H; Cucchiaro J; Loebel A
    Depress Anxiety; 2016 May; 33(5):424-34. PubMed ID: 26918425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.